CN106540123A - 一种调控血糖的复合益生菌素及制备方法 - Google Patents
一种调控血糖的复合益生菌素及制备方法 Download PDFInfo
- Publication number
- CN106540123A CN106540123A CN201611050774.0A CN201611050774A CN106540123A CN 106540123 A CN106540123 A CN 106540123A CN 201611050774 A CN201611050774 A CN 201611050774A CN 106540123 A CN106540123 A CN 106540123A
- Authority
- CN
- China
- Prior art keywords
- powder
- compound probiotic
- seed
- regulating
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 37
- 239000008280 blood Substances 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 239000006041 probiotic Substances 0.000 title claims abstract description 31
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 31
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 31
- 230000001276 controlling effect Effects 0.000 title claims abstract description 16
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 40
- 241000203747 Gordonia terrae Species 0.000 claims abstract description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 21
- 239000008103 glucose Substances 0.000 claims abstract description 21
- 239000007910 chewable tablet Substances 0.000 claims abstract description 19
- 229940068682 chewable tablet Drugs 0.000 claims abstract description 19
- 238000000855 fermentation Methods 0.000 claims abstract description 12
- 230000004151 fermentation Effects 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims abstract description 11
- 239000000654 additive Substances 0.000 claims abstract description 11
- 230000000996 additive effect Effects 0.000 claims abstract description 11
- 235000013336 milk Nutrition 0.000 claims abstract description 11
- 239000008267 milk Substances 0.000 claims abstract description 11
- 210000004080 milk Anatomy 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 238000011081 inoculation Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920001202 Inulin Polymers 0.000 claims abstract description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 5
- 229940029339 inulin Drugs 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000002779 inactivation Effects 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 210000000582 semen Anatomy 0.000 claims abstract description 4
- 239000000811 xylitol Substances 0.000 claims abstract description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 4
- 235000010447 xylitol Nutrition 0.000 claims abstract description 4
- 229960002675 xylitol Drugs 0.000 claims abstract description 4
- 239000012141 concentrate Substances 0.000 claims abstract 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 2
- 229920002907 Guar gum Polymers 0.000 claims description 6
- 239000004376 Sucralose Substances 0.000 claims description 6
- 239000000665 guar gum Substances 0.000 claims description 6
- 229960002154 guar gum Drugs 0.000 claims description 6
- 235000010417 guar gum Nutrition 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- 238000009423 ventilation Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 238000000386 microscopy Methods 0.000 claims description 3
- -1 oatmeal Substances 0.000 claims description 3
- 238000011218 seed culture Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 claims 1
- 229940093503 ethyl maltol Drugs 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract description 9
- 102000004877 Insulin Human genes 0.000 abstract description 6
- 108090001061 Insulin Proteins 0.000 abstract description 6
- 229940125396 insulin Drugs 0.000 abstract description 6
- 238000005550 wet granulation Methods 0.000 abstract description 3
- 230000001079 digestive effect Effects 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 description 19
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 201000002451 Overnutrition Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 235000020823 overnutrition Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000955 splenic vein Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000203749 Gordonia bronchialis Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002243 furanoses Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940055036 mycobacterium phlei Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003716 vitamin K3 derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Abstract
本发明公开了一种调控血糖的复合益生菌素及制备方法，它由一定比例的土生戈登氏菌粉、菊粉、微晶纤维素、木糖醇、牛奶粉、苦荞粉、燕麦粉、南瓜粉、添加剂、柠檬酸组成，步骤是：A、菌种培养：将冻干种子土生戈登氏菌sq‑5接种于茄子瓶斜面，用无菌水转入接种瓶；B、种子罐培养：将接种瓶种子转入种子罐，培养；C、发酵罐培养：将种子罐种子液打入发酵罐，菌体单个球杆状，菌数108－1010个/ml，停止发酵；D、土生戈登氏菌粉制备：将发酵液煮沸灭活后浓缩，烘干收集菌体，得到土生戈登氏菌粉；E、复合益生菌素咀嚼片：将上述原料混合湿法制粒再压片。能有效的清除毒素和脂肪，增强消化功能，改善胰岛素抵抗，调节血糖和血脂。
Description
技术领域
本发明涉及预防医学和微生态学领域，更具体涉及一种调控血糖的复合益生菌素(咀嚼片或胶囊)，同时还涉及一种调控血糖的复合益生菌素(咀嚼片或胶囊)的制备方法，适用于糖尿病人调节和稳定血糖正常水平，还适用于糖尿病高危人群的预防及患者辅助治疗。
背景技术
随着经济的飞速发展，人们生活节奏不断加快，民众的饮食结构发生了很大的变化，营养过剩，比例失调，导致代谢类疾病发病率明显提高，而糖尿病则是其中发病率增长特别迅速的一类疾病。众所周知糖尿病是一种严重威胁人类健康，影响人的生活质量的疾病，60％的患者死于糖尿病性心脏病，36％的患者死于糖尿病性病毒病症，5年内的致盲率超过80％，几乎100％的患者因周围精神病变而终身手脚麻木疼痛，许多患者患糖尿病病足因无法治疗而造成截肢，给个人、家庭和社会造成严重的健康损失和经济损失，认真关注和对待糖尿病已是刻不容缓。目前对于该病的治疗尚无理想的方法，因而不断寻找新的预防和治疗途径是研究者的梦想，并会为此而进行不断探索。
中医学认为糖尿病的发生是痰湿和热盛，也就是说由于营养过剩、比例不当，导致内分泌失调造成的湿热病症。免疫学研究表明免疫功能下降是糖尿病发病的重要因素，而草分支杆菌等益生菌作为免疫调节剂也被广泛用于糖尿病的辅助治疗。营养学和预防医学则认为，糖尿病人的饮食控制疗法是糖尿病预防和治疗的有效方法，那就是低热、低糖、低脂、高纤维素、高维生素、蛋白适中，而复合膳食纤维素包括各类多糖化合物，具有大量吸附代谢毒素和多余脂肪并加速其排出的特殊功能，能有效地改善胰岛素抵抗,调节血糖和血脂。
发明内容
本发明的目的是在于提供了一种调节血糖的复合益生菌素(咀嚼片或胶囊)，配方安全合理，成本低，无污染，使用方便，涉及的是用土生戈登氏菌粉辅以苦荞粉、南瓜粉、牛奶粉、燕麦粉、菊粉等辅料和添加剂制成的复合益生菌素咀嚼片或胶囊。该复合益生菌素咀嚼片或胶囊能全面调整人体脏腑功能，能有效地改善胰岛素抵抗,调节血糖，其降空腹血糖的有效率达到90％，其中67％达到正常值，自觉症状明显改善。
本发明的另一个目的是在于提供了一种调节血糖的复合益生菌素(咀嚼片或胶囊)的制备方法，原料取材来源广泛，利用率高；工艺简单易行、便于推广，适用于大规模生产。
为了达到上述的目的，本发明采取以下技术措施：
一种调节血糖的复合益生菌素(咀嚼片或胶囊)，它由以下重量份的原料制成：
所述的添加剂组成为：奶香精(0.025-0.05份)、枣香精(0.025-0.05份)、乙基麦芽酚(0.01-0.015份)、瓜尔胶(0.03-0.05份)、三氯蔗糖(0.0025-0.005份)其中的任何一种或二至五种的任意混合。
一种调控血糖的复合益生菌素(咀嚼片或胶囊)，它由以下重量份的原料制成(优选范围)：
所述的添加剂组成为：奶香精(0.025-0.05份)、枣香精(0.025-0.05份)、乙基麦芽酚(0.01-0.015份)、瓜尔胶(0.03-0.05份)、三氯蔗糖(0.0025-0.005份)其中的任何一种或二至五种的任意混合。
一种调控血糖的复合益生菌素(咀嚼片或胶囊)，它由以下重量份的原料制成(最好范围)：
所述的添加剂组成为：奶香精(0.025-0.05份)、枣香精(0.025-0.05份)、乙基麦芽酚(0.01-0.015份)、瓜尔胶(0.03-0.05份)、三氯蔗糖(0.0025-0.005份)其中的任何一种或二至五种的任意混合。
一种调控血糖的复合益生菌素(咀嚼片或胶囊)，它由以下重量份的原料制成(最佳值)：
所述的添加剂组成为：奶香精(0.025-0.05份)、枣香精(0.025-0.05份)、乙基麦芽酚(0.01-0.015份)、瓜尔胶(0.03-0.05份)、三氯蔗糖(0.0025-0.005份)其中的任何一种或二至五种的任意混合。
一种调控血糖的复合益生菌素(咀嚼片或胶囊)的制备方法，其步骤是：
A、菌种培养：斜面种子培养基察氏培养基，将冻干种子土生戈登氏菌sq-5(ZL201310016059.5)接种于茄子瓶斜面，温度控制在28－32℃，培养3天。检查无杂菌，生长健壮，均匀，用无菌水转入接种瓶。
B、种子罐培养：将A中所述接种瓶种子转入种子罐，培养温度28－32℃，通气量1:0.6－0.8，自动流加泡敌，培养30－35h，取样镜检，合格后备用。
C、发酵罐培养：以5－10％的接种量将上述B中种子罐种子液打入发酵罐，通气量1:0.8，自动流加泡敌，温度控制在28－32℃，培养48－52h，菌体单个球杆状，菌数108－1010个/ml，停止发酵。
D、土生戈登氏菌粉制备：将上述C中培养好的发酵液100℃煮沸灭活后浓缩，浓缩物108－112℃烘干收集菌体，粉碎过筛(120目)，得到土生戈登氏菌粉。
E、复合益生菌素(咀嚼片或胶囊)的制备：按重量份将土生戈登氏菌粉、菊粉、微晶纤维素、木糖醇、柠檬酸、苦荞粉、南瓜粉、牛奶粉、燕麦粉、添加剂进行混合，获得一种复合益生菌素，然后将复合益生菌素采用湿法制粒再压片或制成胶囊、包装制成。
所述的土生戈登氏菌sq-5(Gordona terrae sq-5)保存于武汉大学中国典型培养物保藏中心，编号为CCTCC NO:M2012390。该菌为专利菌种，专利号为:ZL2013 10016059.5。
所述的种子罐和发酵罐发酵用培养基配方：
与现有技术比较的复合益生菌素咀嚼片或胶囊具有如下优点：
土生戈登氏菌等戈登氏菌和草分枝杆菌一样，它们有着共同的细胞壁结构，含有胞壁酰二肽(MDP)，它是壁中最小的免疫活性单位，而壁的外层是酸性粘多糖，包含有阿拉伯糖和半乳糖二者以3:1形式连接，而阿拉伯糖的呋喃糖残基则是免疫决定簇，因而赋予了这类菌特殊的免疫调节功能。
该菌的培养物中含有胡萝卜素、黄酮、甲基萘醌等天然抗氧化因子，赋予该菌粉很好的抗氧化功能。
该保健品含有很多膳食纤维，能有效的清除毒素和脂肪，增强消化功能，改善胰岛素抵抗，调节血糖和血脂。
土生戈登氏菌粉经功能性实验证明其具有明显的辅助降血糖、提高免疫力的功能。
本发明配方制成的咀嚼片经初步人体试食试验证明其调节空腹血糖的有效率达到90％，其中67％达到正常值；尿糖显著下降；自觉症状明显改善。
本发明的原料来源广泛，工艺简单易操作。
具体实施方式
本发明的实施例中的实验方法或条件,如未特别说明均为常规方案。
实施例1：
一种调控血糖的复合益生菌素(咀嚼片或胶囊)，它由以下重量份的原料制成：
所述的添加剂组成为：奶香精(0.025-0.05份)、枣香精(0.025-0.05份)、乙基麦芽酚(0.01-0.015份)、瓜尔胶(0.03-0.05份)、三氯蔗糖(0.0025-0.005份)其中的任何一种或二至五种的任意混合。
所述的土生戈登氏菌sq-5(Gordona terrae sq-5)CCTCC NO：M2012390。
一种调控血糖的复合益生菌素(咀嚼片或胶囊)，它由以下重量份的原料制成：
制备方法与实施例1相同。
实施例8：
一种调控血糖的复合益生菌素(咀嚼片或胶囊)的制备方法，其步骤是：
A、菌种培养：斜面种子培养基察氏培养基，将冻干种子土生戈登氏菌sq-5(专利号为:ZL2013 1 0016059.5)接种于茄子瓶斜面，28或29或30或31或32℃培养3天。检查无杂菌，生长健壮，均匀，用无菌水转入接种瓶。
B、种子罐培养：将A中所述接种瓶种子转入种子罐，培养温度28或29或30或31或32℃，通气量1:0.6或0.7或0.8，自动流加泡敌，培养30或32或34或35h，取样镜检，合格后备用。
C、发酵罐培养：以5％或7％或9％或10％的接种量将上述B中种子罐种子液打入发酵罐，通气量1:0.8，自动流加泡敌，28或29或30或31或32℃培养48或50或52h，菌体单个球杆状，菌数108或109或1010个/ml，停止发酵。
D、土生戈登氏菌粉制备：将上述C中培养好的发酵液100℃煮沸灭活后浓缩，浓缩物108或109或110或111或112℃烘干收集菌体，粉碎过筛(120目)，得到土生戈登氏菌粉。
E、复合益生菌素(咀嚼片或胶囊)的制备：按重量份将土生戈登氏菌粉、菊粉、微晶纤维素、木糖醇、柠檬酸、苦荞粉、南瓜粉、牛奶粉、燕麦粉、添加剂进行混合，获得一种复合益生菌素，然后将复合益生菌素采用湿法制粒再压片或制成胶囊(常规技术)、包装制成。
种子罐和发酵罐发酵用培养基配方
实施例9：
土生戈登氏菌sq-5全细胞菌粉对小鼠免疫功能影响，其步骤是：
实验动物为昆明种雄性小鼠62只，体重为20±2g，随机分成四组，蒸馏水+饲料组(CK)20只，分别在饲料中加土生戈登氏菌粉0.0001g，0.001g，0.01g各14只，连续喂养14天，于第15天进行脾淋巴细胞转化，诱导产生IL-2、TNF及胸腺重量的实验，其结果见表1和表2。
表1土生戈登氏菌sq-5菌粉对脾淋巴细胞转化影响
| 组别 | 小鼠个数N | 生理盐水 | conA诱导 |
| CK | 20 | 3800±437 | 11258±1713 |
| 0.0001 | 14 | 8343±402 | 18307±3143 |
| 0.001 | 14 | 11286±2317 | 24532±4315 |
| 0.01 | 14 | 12688±1302 | 29563±2811 |
三个计量组与CK组比P＜0.01，显著增加小鼠的脾淋巴细胞的转化。
表2土生戈登氏菌sq-5对小鼠IL-2、TNF及胸腺重量的影响
各剂量组与CK组比P＜0.01
由此说明土生戈登氏菌粉明显提高脾淋巴细胞的转化并产生IL-2水平得以提高显著，并能显著提高腹腔巨噬细胞诱导TNF的能力，明显增加小鼠胸腺的重量，也就是说该药剂可以提高小鼠的免疫功能。
实施例10：
土生戈登氏菌粉对糖尿病模型小鼠糖代谢影响实验步骤如下：
选3月龄昆明小鼠,体重20±2g，随机分成CK组、土生戈登氏菌粉和南瓜粉共3组实验。
模型的建立：3组动物均建模，小鼠胸腔注射链脲佐菌素4ml/kg·d，连续5天，10天后禁食6h测血糖，待形成实验性糖尿病鼠动物模型后给予实验给药：土生戈登氏菌粉组每天0.01g，以及南瓜粉0.01g，加1ml生理盐水溶解后分两次灌胃，CK组用等量生理盐水灌胃。实验时间为8周，分别于实验前和建立糖尿病模型禁食6h后剪尾测血糖，最后采小鼠眶动脉血用葡萄糖氧化酶法测定血糖变化；放射免疫分析法测定血浆胰岛素水平。结果见表3和表4。
表3造模前后血糖的变化
| 组别 | 数量N | 造模前 | 造模后mmol/l |
| CK | 10 | 5.41±1.03 | 8.93±2.21 |
| 土生戈登氏菌粉 | 10 | 6.01±0.16 | 8.89±1.83 |
| 南瓜粉 | 10 | 5.96±1.23 | 8.77±1.73 |
造模后各组血糖都明显提高形成了实验性糖尿病模型
表4各组实验前后血糖和胰岛素水平变化
实验后的血糖与实验前比较都明显降低，而CK组反而增加，同时血浆胰岛素水平明显高于CK组，土生戈登氏菌粉效果优于南瓜粉组。
实施例11：
采用上述实施的功能产品，在市级以上医院选出40-70岁的2型糖尿病患者12例进行初步试验，在其中男4人，女8人，停用一切降糖药，服用上述食品，每次5片，每日3次，饭前30分钟服用，服用前后逐人分别检测血糖，尿糖，结果如下表：
结果表明：1.降空腹血糖的有效率90％，其中67％达到正常值；2.尿糖显著下降；3自觉症状，包括尿多，口渴，饥饿，无力多汗等按总分评定，自觉症状显著改善占70％、有效率占25％、无效占5％。
Claims (5)
1.一种调节血糖的复合益生菌素，它由以下重量份的原料制成：
所述的添加剂组成为：奶香精：0.025-0.05份、枣香精：0.025-0.05份、乙基麦芽酚：0.01-0.015份、瓜尔胶：0.03-0.05份、三氯蔗糖：0.0025-0.005份其中的任何一种或二至五种的任意混合。
2.根据权利要求1所述的一种调控血糖的复合益生菌素，其特征在于：
3.根据权利要求1所述的一种调控血糖的复合益生菌素，其特征在于：
4.根据权利要求1所述的一种调控血糖的复合益生菌素，其特征在于：
5.权利要求1所述的一种调控血糖的复合益生菌素的制备方法，其步骤是：
A、菌种培养：斜面种子培养基察氏培养基，将冻干种子土生戈登氏菌sq-5接种于茄子瓶斜面，温度控制在28－32℃，培养3天，检查无杂菌，生长健壮，均匀，用无菌水转入接种瓶；
B、种子罐培养：将步骤A中所述接种瓶种子转入种子罐，培养温度28－32℃，通气量1:0.6－0.8，自动流加泡敌，培养30－35h，取样镜检，合格后备用；
C、发酵罐培养：以5－10％的接种量将步骤B中种子罐种子液打入发酵罐，通气量1:0.8，自动流加泡敌，温度控制在28－32℃，培养48－52h，菌体单个球杆状，菌数108－1010个/ml，停止发酵；
D、土生戈登氏菌粉制备：将步骤C中培养的发酵液100℃煮沸灭活后浓缩，浓缩物108－112℃烘干收集菌体，粉碎过筛，得到土生戈登氏菌粉；
E、复合益生菌素咀嚼片：按重量份将土生戈登氏菌粉、菊粉、微晶纤维素、木糖醇、柠檬酸、苦荞粉、南瓜粉、牛奶粉、燕麦粉、添加剂进行混合，获得一种复合益生菌素。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611050774.0A CN106540123B (zh) | 2016-11-23 | 2016-11-23 | 一种调控血糖的复合益生菌素及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611050774.0A CN106540123B (zh) | 2016-11-23 | 2016-11-23 | 一种调控血糖的复合益生菌素及制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106540123A true CN106540123A (zh) | 2017-03-29 |
| CN106540123B CN106540123B (zh) | 2018-06-29 |
Family
ID=58395001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611050774.0A Active CN106540123B (zh) | 2016-11-23 | 2016-11-23 | 一种调控血糖的复合益生菌素及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106540123B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007071986A1 (en) * | 2005-12-21 | 2007-06-28 | Bioeos Limited | Use of whole bacterial cells (actinomycetales) for maternal administration to modulate offspring immune response |
| CN101341949A (zh) * | 2008-08-25 | 2009-01-14 | 中国农业大学 | 一种杂粮咀嚼片及其制备方法 |
| CN103060240A (zh) * | 2013-01-16 | 2013-04-24 | 张素琴 | 一种解毒微生物发酵剂及制备方法和应用 |
| CN103555630A (zh) * | 2013-11-05 | 2014-02-05 | 张素琴 | 一种中华戈登氏菌及制备方法和应用 |
-
2016
- 2016-11-23 CN CN201611050774.0A patent/CN106540123B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007071986A1 (en) * | 2005-12-21 | 2007-06-28 | Bioeos Limited | Use of whole bacterial cells (actinomycetales) for maternal administration to modulate offspring immune response |
| CN101341949A (zh) * | 2008-08-25 | 2009-01-14 | 中国农业大学 | 一种杂粮咀嚼片及其制备方法 |
| CN103060240A (zh) * | 2013-01-16 | 2013-04-24 | 张素琴 | 一种解毒微生物发酵剂及制备方法和应用 |
| CN103555630A (zh) * | 2013-11-05 | 2014-02-05 | 张素琴 | 一种中华戈登氏菌及制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106540123B (zh) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102239972B (zh) | 用于提高断奶仔猪免疫力及抗寄生虫感染的中药饲料添加剂及其制备和使用方法 | |
| CN101624570B (zh) | 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法 | |
| CN101965969A (zh) | 一种具有抗疲劳和提高免疫功能保健食品组合物及其制备方法和用途 | |
| CN103750339B (zh) | 雪莲培养物保健食品及其用途 | |
| CN106721803A (zh) | 一种富硒海蓬子保健饮料 | |
| CN103636946A (zh) | 一种黄鳝用中草药免疫增强剂的制备方法及应用 | |
| CN109528814B (zh) | 一种乳酸菌发酵黄芪的微生态制剂及其制备方法和应用 | |
| CN103637185B (zh) | 神经酸组合物 | |
| CN106418525A (zh) | 一种发酵型桑叶咀嚼片及其制备方法 | |
| CN105495560A (zh) | 一种复合植物多糖与菌类多糖的营养食品 | |
| CN103495136B (zh) | 一种治疗畜禽胃肠道寄生虫病的发酵中草药及其制备方法 | |
| CN104522750A (zh) | 一种藻类保健食品 | |
| CN104799289B (zh) | 具有抗肿瘤提高免疫功能的复合营养食品及其生产方法 | |
| CN107212392A (zh) | 一种全营养发酵养生食品及其制备方法 | |
| CN107095300A (zh) | 一种辅助治疗糖尿病的生物营养配方组合物 | |
| CN102488213B (zh) | 一种生物有机营养液 | |
| CN106389477B (zh) | 一种土生戈登氏菌的全细胞植物油提取物的制备方法和应用 | |
| CN106540123A (zh) | 一种调控血糖的复合益生菌素及制备方法 | |
| CN104106799A (zh) | 一种具有清除体内毒素作用的组合物及其制备方法 | |
| CN101361800A (zh) | 降血脂及增效减毒他汀类药物作用的中药及其制备方法 | |
| CN104189038B (zh) | 用于调理女性生理健康和免疫功能的中药制剂 | |
| CN114028509A (zh) | 一种疏肝健脾活血的药食同源组合物及其制备方法 | |
| CN1296059C (zh) | 草分支杆菌免疫液 | |
| CN102319355B (zh) | 一种治疗多动症的中药组方及其丸剂的制备方法 | |
| CN111265627B (zh) | 一种调节肠道菌群的海参多糖组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180323 Address after: Room 523, room No. 1, B District, B District, Wuhan, East Lake New Technology Development Zone, Wuhan City, Hubei Applicant after: Wuhan Qi Yao Biological Technology Co.,Ltd. Address before: 430079 Hubei City, Wuhan Province, East Lake Development Zone, hung Chu street, No. 998, No. 10 Online sunshine 2-402 Applicant before: WUHAN QIYAO ENVIRONMENTAL TECHNOLOGY CO.,LTD. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190708 Address after: 430042 No. 43, Maomiao Market Street, Baiquan, Dongxihu District, Wuhan City, Hubei Province (9) Patentee after: Wuhan Taoyuanfeng Holding Co.,Ltd. Address before: 430000 Room 523, Building 1, B, Headquarters of Gaonong Biological Park, 888 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee before: Wuhan Qi Yao Biological Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191128 Address after: 430000 room b011, public service center, daolongquan mountain scenic spot, 004 County, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan runshui Environmental Technology Co.,Ltd. Address before: 430042 No. 43, Maomiao Market Street, Baiquan, Dongxihu District, Wuhan City, Hubei Province (9) Patentee before: Wuhan Taoyuanfeng Holding Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230628 Address after: No. 64-5-10, Xiaohongshan District, Wuchang District, Wuhan City, Hubei Province 430000 Patentee after: Zhang Shimin Patentee after: Zhang Suqin Address before: 430000 room b011, public service center, Longquanshan scenic area, 004 County Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee before: Wuhan runshui Environmental Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |